The influence of NK cell-mediated ADCC: Structure and expression of the CD16 molecule differ among FcγRIIIa-V158F genotypes in healthy Japanese subjects

Human Immunology

Volumn 77, Issue 2, 2016, Pages 165-171

  Oboshi, Wataru ^a,b   Watanabe, Toru ^a   Matsuyama, Yuumi ^a   Kobara, Ayana ^a   Yukimasa, Nobuyasu ^a   Ueno, Ichiro ^a   Aki, Kensaku ^c   Tada, Tomoki ^b   Hosoi, Eiji ^c  

^a KAGAWA PREFECTURAL UNIVERSITY OF HEALTH SCIENCES   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Antibody dependent cellular cytotoxicity (ADCC); CD16 molecule; Fc RIIIa V158F polymorphism; NK cells; Rituximab binding affinity; Single nucleotide polymorphisms (SNPs)

Indexed keywords

CD16 ANTIGEN; FC RECEPTOR; FC RECEPTOR IIIA; GENOMIC DNA; UNCLASSIFIED DRUG; PROTEIN BINDING;

ADULT; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BINDING AFFINITY; DNA POLYMORPHISM; FCGR3A GENE; FEMALE; GENE; GENE EXPRESSION; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN EXPERIMENT; JAPANESE (PEOPLE); MALE; NATURAL KILLER CELL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; ADOLESCENT; CHEMISTRY; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETICS; IMMUNOLOGY; JAPAN; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; FEMALE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENOTYPE; HUMANS; JAPAN; KILLER CELLS, NATURAL; MALE; PROTEIN BINDING; RECEPTORS, IGG; YOUNG ADULT;

EID: 84958117862     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2015.11.001     Document Type: Article

References (41)

1. Robertson M.J., Ritz J. Biology and clinical relevance of human natural killer cells. Blood 1990, 76:2421-2438.
2. Farag S.S., Van Deusen J.B., Fehniger T.A., Caligiuri M.A. Biology and clinical impact of human natural killer cells. Int. J. Hematol. 2003, 78:7-17.
3. Farag S.S., Caligiuri M.A. Human natural killer cell development and biology. Blood Rev. 2006, 20:123-137.
4. Alderson K.L., Sondel P.M. Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. J. Biomed. Biotechnol. 2011, 2011.
5. Weiner L.M., Surana R., Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 2010, 10:317-327.
6. Kubota T., Niwa R., Satoh M., Akinaga S., Shitara K., Hanai N. Engineered therapeutic antibodies with improved effector functions. Cancer Sci. 2009, 100:1566-1572.
7. Winter M.C., Hancock B.W. Ten years of rituximab in NHL. Expert Opin. Drug Saf. 2009, 8:223-235.
8. Arnould L., Gelly M., Penault-Llorca F., Benoit L., Bonnetain F., Migeon C., et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?. Br. J. Cancer 2006, 94:259-267.
9. Lazar G.A., Dang W., Karki S., Vafa O., Peng J.S., Hyun L., et al. Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:4005-4010.
10. Manches O., Lui G., Chaperot L., Gressin R., Molens J.P., Jacob M.C., et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003, 101:949-954.
11. Ljunggren H.G., Malmberg K.J. Prospects for the use of NK cells in immunotherapy of human cancer. Nat. Rev. Immunol. 2007, 7:329-339.
12. Marcus R., Hagenbeek A. The therapeutic use of rituximab in non-Hodgkin's lymphoma. Eur. J. Haematol. Suppl. 2007, 67:5-14.
13. Leibson P.J. Signal transduction during natural killer cell activation: inside the mind of a killer. Immunity 1997, 6:655-661.
14. Koene H.R., Kleijer M., Algra J., Roos D., von dem Borne A.E., de Haas M. Fc RIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FcRIIIa, independently of the FcRIIIa-48L/R/H phenotype. Blood 1997, 90:1109-1114.
15. Wu J., Edberg J.C., Redecha P.B., Bansal V., Guyre P.M., Coleman K., et al. A novel polymorphism of FcRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J. Clin. Invest. 1997, 100:1059-1070.
16. Vance B.A., Huizinga T.W., Wardwell K., Guyre P.M. Binding of monomeric human IgG defines an expression polymorphism of Fc RIII on large granular lymphocyte/natural killer cells. J. Immunol. 1993, 151:6429-6439.
17. de Haas M., Koene H.R., Kleijer M., de Vries E., Simsek S., van Tol M.J., et al. A triallelic Fc gamma receptor type IIIA polymorphism influences the binding of human IgG by NK cell Fc gamma RIIIa. J. Immunol. 1996, 156:2948-2955.
18. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002, 99:754-758.
19. Collins-Burow B., Santos E.S. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma. Drugs 2003, 63:803-843.
20. Plosker G.L., Figgitt D.P. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Expert Rev. Anticancer Ther. 2007, 7:257-273.
21. Keating G.M. Spotlight on rituximab in chronic lymphocytic leukemia, low-grade or follicular lymphoma, and diffuse large B-cell lymphoma. BioDrugs 2011, 25:55-61.
22. Treon S.P., Hansen M., Branagan A.R., Verselis S., Emmanouilides C., Kimby E., et al. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. J. Clin. Oncol. 2005, 23:474-481.
23. Mellor J.D., Brown M.P., Irving H.R., Zalcberg J.R., Dobrovic A. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J. Hematol. Oncol. 2013, 6:1.
24. Weng W.K., Negrin R.S., Lavori P., Horning S.J. Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma. J. Clin. Oncol. 2010, 28:279-284.
25. Bibeau F., Lopez-Crapez E., Di Fiore F., Thezenas S., Ychou M., Blanchard F., et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J. Clin. Oncol. 2009, 27:1122-1129.
26. Musolino A., Naldi N., Bortesi B., Pezzuolo D., Capelletti M., Missale G., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 2008, 26:1789-1796.
27. Zhang W., Gordon M., Schultheis A.M., Yang D.Y., Nagashima F., Azuma M., et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J. Clin. Oncol. 2007, 25:3712-3718.
28. Kim D.H., Jung H.D., Kim J.G., Lee J.J., Yang D.H., Park Y.H., et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood 2006, 108:2720-2725.
29. Wu J., Edberg J.C., Redecha P.B., Bansal V., Guyre P.M., Coleman K., et al. A novel polymorphism of FcgammaRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J. Clin. Invest. 1997, 100:1059-1070.
30. Hatjiharissi E., Xu L., Santos D.D., Hunter Z.R., Ciccarelli B.T., Verselis S., et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood 2007, 110:2561-2564.
31. Congy-Jolivet N., Bolzec A., Ternant D., Ohresser M., Watier H., Thibault G. Fc gamma RIIIa expression is not increased on natural killer cells expressing the Fc gamma RIIIa-158V allotype. Cancer Res. 2008, 68:976-980.
32. Zaritskaya L., Shurin M.R., Sayers T.J., Malyguine A.M. New flow cytometric assays for monitoring cell-mediated cytotoxicity. Expert Rev. Vaccin. 2010, 9:601-616.
33. Cao L.F., Krymskaya L., Tran V., Mi S., Jensen M.C., Blanchard S., et al. Development and application of a multiplexable flow cytometry-based assay to quantify cell-mediated cytolysis. Cytometry A 2010, 77:534-545.
34. Scherbakova A., Lust H., Everaus H., Aints A. A mathematical model of natural killer cell activity. Cytometry A 2013, 83:585-591.
35. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
36. Rodriguez S., Gaunt T.R., Day I.N. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am. J. Epidemiol. 2009, 169:505-514.
37. Ravetch J.V., Perussia B. Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions. J. Exp. Med. 1989, 170:481-497.
38. Sachidanandam R., Weissman D., Schmidt S.C., Kakol J.M., Stein L.D., Marth G., et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 2001, 409:928-933. International SNP Map Working Group.
39. Collins F.S., Brooks L.D., Chakravarti A. A DNA polymorphism discovery resource for research on human genetic variation. Genome Res. 1998, 8:1229-1231.
40. Kyogoku C., Tsuchiya N., Matsuta K., Tokunaga K. Studies on the association of Fc gamma receptor IIA, IIB, IIIA and IIIB polymorphisms with rheumatoid arthritis in the Japanese: evidence for a genetic interaction between HLA-DRB1 and FCGR3A. Genes Immun. 2002, 3:488-493.
41. Radaev S., Motyka S., Fridman W.H., Sautes-Fridman C., Sun P.D. The structure of a human type III Fcgamma receptor in complex with Fc. J. Biol. Chem. 2001, 276:16469-16477.